GH Research PLC (NASDAQ:GHRS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of GH Research PLC (NASDAQ:GHRS) have received an average rating of “Moderate Buy” from the twelve analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $34.1111.

A number of research analysts have issued reports on the company. TD Cowen reiterated a “buy” rating on shares of GH Research in a research report on Monday, January 5th. HC Wainwright cut their price objective on shares of GH Research from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Guggenheim reiterated a “buy” rating and issued a $29.00 target price on shares of GH Research in a research report on Monday, January 5th. Citigroup reissued a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research note on Thursday.

GH Research Trading Down 0.1%

Shares of NASDAQ:GHRS opened at $16.73 on Monday. The firm’s 50 day moving average is $14.44 and its two-hundred day moving average is $14.01. GH Research has a 52 week low of $7.98 and a 52 week high of $20.50. The firm has a market capitalization of $870.46 million, a P/E ratio of -22.61 and a beta of 0.98.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Analysts predict that GH Research will post -0.8 EPS for the current year.

Hedge Funds Weigh In On GH Research

Several hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. lifted its position in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after acquiring an additional 2,400 shares during the last quarter. AdvisorShares Investments LLC raised its position in shares of GH Research by 15.0% during the second quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company’s stock worth $466,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of GH Research during the second quarter valued at $79,000. Virtus Investment Advisers LLC acquired a new position in shares of GH Research in the 2nd quarter valued at $89,000. Finally, BNP Paribas Financial Markets boosted its position in shares of GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the period. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.